# Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy

> **NCT02710253** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 230 (estimated)

## Conditions studied

- Hematopoietic and Lymphoid Cell Neoplasm
- Metastatic Malignant Solid Neoplasm

## Interventions

- **RADIATION:** External Beam Radiation Therapy
- **OTHER:** Laboratory Biomarker Analysis
- **RADIATION:** Stereotactic Body Radiation Therapy

## Key facts

- **NCT ID:** NCT02710253
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-05-25
- **Primary completion:** 2027-05-30
- **Final completion:** 2027-05-30
- **Target enrollment:** 230 (ESTIMATED)
- **Last updated:** 2026-05-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02710253

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02710253, "Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT02710253. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*